Downgrades Buy Neutral X

ARVN Arvinas

Goldman

$70 $15

Downgrades Outperform Neutral X

ARVN Arvinas

Wedbush

$57 $12

Downgrades Outperform Perform X

ARVN Arvinas

Oppenheimer

Initiated Buy X

ARVN Arvinas

BTIG Research

$69

Initiated Overweight X

ARVN Arvinas

Stephens

$55

Reiterated Outperform X

ARVN Arvinas

Oppenheimer

$95 $80

Downgrades Buy Neutral X

ARVN Arvinas

Citigroup

$36 $55

Upgrades Eq Weight Overweight X

ARVN Arvinas

Wells Fargo

$25 $63

Upgrades Hold Buy X

ARVN Arvinas

Jefferies

$40

Upgrades Neutral Buy X

ARVN Arvinas

Guggenheim

Upgrades Neutral Outperform X

ARVN Arvinas

Wedbush

$27 $24

Resumed Outperform X

ARVN Arvinas

Oppenheimer

$95

Downgrades Buy Neutral X

ARVN Arvinas

Guggenheim

Downgrades Overweight Eq Weight X

ARVN Arvinas

Wells Fargo

$83 $49

Initiated Overweight X

ARVN Arvinas

Barclays

$90

Initiated Hold X

ARVN Arvinas

Jefferies

$42

Downgrades Outperform Neutral X

ARVN Arvinas

Wedbush

Initiated Outperform X

ARVN Arvinas

Credit Suisse

$104

Resumed Outperform X

ARVN Arvinas

BMO Capital Markets

$125

Initiated Overweight X

ARVN Arvinas

Wells Fargo

$98

Initiated Buy X

ARVN Arvinas

Goldman

$157

Initiated Outperform X

ARVN Arvinas

Cowen

Initiated Outperform X

ARVN Arvinas

SVB Leerink

$115

Initiated Buy X

ARVN Arvinas

UBS

$123

Initiated Buy X

ARVN Arvinas

Truist

$150

Initiated Outperform X

ARVN Arvinas

BMO Capital Markets

$101

Initiated Overweight X

ARVN Arvinas

Cantor Fitzgerald

$42

Downgrades Buy Neutral X

ARVN Arvinas

Citigroup

$21 $22

Initiated Outperform X

ARVN Arvinas

Evercore ISI

Initiated Buy X

ARVN Arvinas

Citigroup

$21

Initiated Neutral X

ARVN Arvinas

Goldman

$17

Initiated Overweight X

ARVN Arvinas

Piper Jaffray

$23

ARVN  Arvinas Holding Company, LLC

Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.